|
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Soluble C5b-9 (sMAC)
Test Code11388
CPT Codes
83520<br><strong>This test is not available for New York patient testing.</strong><br>Restricted Client Code
Preferred Specimen
2 mL frozen plasma collected in an EDTA (lavender-top) tube
Patient Preparation
PLEX treatments will affect plasma tests. Please wait approximately 14 days after PLEX to draw samples.
Minimum Volume
1 mL
Instructions
Plasma samples must be processed and frozen down to -80° C (or on dry ice) immediately after collection (please see instructions).
Sample type must be clearly labeled "plasma" and shipped out overnight on at least 5 lb. dry ice (Monday - Thursday).
1.Follow standard phlebotomy techniques to collect at least 6 cc of whole blood drawn in a lavender-top vacutainer tube.
2.Centrifuge the clotted blood at room temperature (1000 x g for 10 minutes).
3.Label "Plasma" on clean screw top-tube(s).
4.Pipette cell-free supernatant (at least 2 mL) to each labeled tube(s).
5.Place the tube immediately at -80° C (or on dry ice). Sample must remain deep frozen.
Note: Do not transfer cells with plasma. If necessary centrifuge a second time.
Plasma must be frozen, and samples must be shipped overnight with a minimum of 2.4 kg (or 5 lb.) dry ice.
-Delivery: Monday-Friday. No weekend deliveries
All requested information must be provided, or testing will not be performed.
Patient information:
Patient date of birth and gender
Patient ethnicity and race
Patient's clinical information and family history of kidney
disease
Specimen information:
Patient identifiers (full name, date of birth, sex, and medical record number)
Date of collection
Sample type - frozen samples must be clearly labeled as plasma
Ordering physician
Sample type must be clearly labeled "plasma" and shipped out overnight on at least 5 lb. dry ice (Monday - Thursday).
1.Follow standard phlebotomy techniques to collect at least 6 cc of whole blood drawn in a lavender-top vacutainer tube.
2.Centrifuge the clotted blood at room temperature (1000 x g for 10 minutes).
3.Label "Plasma" on clean screw top-tube(s).
4.Pipette cell-free supernatant (at least 2 mL) to each labeled tube(s).
5.Place the tube immediately at -80° C (or on dry ice). Sample must remain deep frozen.
Note: Do not transfer cells with plasma. If necessary centrifuge a second time.
Plasma must be frozen, and samples must be shipped overnight with a minimum of 2.4 kg (or 5 lb.) dry ice.
-Delivery: Monday-Friday. No weekend deliveries
All requested information must be provided, or testing will not be performed.
Patient information:
Patient date of birth and gender
Patient ethnicity and race
Patient's clinical information and family history of kidney
disease
Specimen information:
Patient identifiers (full name, date of birth, sex, and medical record number)
Date of collection
Sample type - frozen samples must be clearly labeled as plasma
Ordering physician
Transport Container
Transport tube
Transport Temperature
Frozen
Specimen Stability
Room temperature: Unacceptable
Refrigerated: Unacceptable
Frozen: Indefinitely
Refrigerated: Unacceptable
Frozen: Indefinitely
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Thawed • Unlabeled samples
Methodology
Enzyme-Linked Immunosorbent Assay (ELISA)
FDA Status
This test was developed and its performance characteristics determined by the Clinical Diagnostics Division of the Molecular Otolaryngology & Renal Research Laboratories. It has not been cleared or approved by the US Food and Drug Administration.
Setup Schedule
Set up: As needed; Report available: 14 days
Reference Range
Negative
Clinical Significance
Hemolytic Assay - Sheep Erythrocyte Lysis Assay
Sheep erythrocytes are non-activating surfaces. This assay measures complement-mediated lysis of sheep erythrocytes secondary to activation of the alternative pathway (AP). Lysis can be seen in the serum of patients with aHUS and DDD.
Indications for screening: Screening is appropriate for patients with aHUS and biopsy-proven DDD.
Sheep erythrocytes are non-activating surfaces. This assay measures complement-mediated lysis of sheep erythrocytes secondary to activation of the alternative pathway (AP). Lysis can be seen in the serum of patients with aHUS and DDD.
Indications for screening: Screening is appropriate for patients with aHUS and biopsy-proven DDD.